The companion diagnostics market size was estimated at USD 10.25 billion in 2025 and is projected to increase from USD 11.28 billion in 2026 to approximately USD 26.80 billion by 2035, growing at a CAGR of 10.09% from 2026 to 2035. The companion diagnostics market is driven by the increasing shift toward precision medicine, rising cancer incidence, and pharmaceutical and diagnostic companies are increasingly collaborating to pair new therapies with diagnostic tests, which ensures faster regulatory approvals and long-term cost-effectiveness.
Companion diagnostics comprises specialized medical tests designed to match a patient with a specific drug or therapy. It offers the critical advantages of identifying which patients are most likely to benefit from a treatment and which are at risk for serious adverse side effects. In applications, such as oncology and infectious diseases, this ensures targeted, personalized care that maximizes clinical efficacy and prevents ineffective treatments.
The growing shift away from one-size-fits-all treatments toward individualized healthcare based on a patient's unique genetic profile and biomarkers. This trend is fundamentally altering how drugs are prescribed, especially in oncology, to ensure targeted therapies yield the highest possible efficacy and fewest adverse side effects.
While traditionally dominated by cancer treatments, companion diagnostics are now rapidly expanding into other therapeutic areas, including neurology, cardiology, and infectious diseases. These broader applications allow healthcare providers to apply targeted, biomarker-driven therapies to a wide variety of complex conditions.
The adoption of next-generation sequencing and less-invasive liquid biopsies has enabled more comprehensive and rapid genomic profiling. These advanced technologies allow clinicians to detect immune-oncology biomarkers from a simple blood draw, making it easier to track disease mutations and tailor therapies over time without requiring invasive tissue biopsies.
AI is transforming the companion diagnostics industry by accelerating the identification of subtle biomarkers and genetic mutations from complex data, such as next-generation sequencing and digital pathology. By replacing manual interpretation with predictive modeling, AI-driven algorithms improve the precision and speed of testing, leading to more accurate patient stratification. This targeted approach significantly refines clinical decision-making and reduces trial-and-error prescribing in precision oncology.
| Report Coverage | Details |
| Market Size in 2026 | USD 11.28 Billion |
| Market Size by 2035 | USD 26.80 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 10.09% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Product & Service, Indication, Technology, Sample Type, End Use, Region |
| Market Analysis (Terms Used) | Value (USD Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | QIAGEN; Agilent Technologies, Inc.; Abbott; Thermo Fisher Scientific, Inc.; F. Hoffmann La Roche Ltd; Foundation Medicine; Myriad Genetics; Illumina, Inc.; BioMérieux; Leica Biosystems; Guardant Health, Inc.; EntroGen, Inc. |
Rising of Precision Medicine
The necessity of highly personalized, biomarker-driven therapies over traditional, broad-spectrum treatments. Because targeted drugs are only effective in specific patient subsets, pharmaceutical companies are increasingly co-developing corresponding diagnostic tests to accurately identify which individuals will respond positively. This symbiotic approach, which is highly encouraged by regulatory bodies, ensures better clinical outcomes, minimizes adverse drug reactions, and streamlines the drug approval process.
High Development Cost
The market growth is hindered by the substantial capital investments required for biomarker discovery, analytical validation, and synchronized clinical trials with pharmaceutical partners. Many of these co-developed drugs fail in late-stage clinical trials, and the associated diagnostic investments often result in a low cost-benefit ratio.
Expanding Applications and Advanced Diagnostics
By leveraging innovations, pharmaceutical companies can co-develop highly targeted therapies and expand companion diagnostics into non-oncology fields, such as infectious diseases and neurological disorders. This broader application and enhanced precision significantly reduce the risk of adverse drug reactions, ensuring greater therapeutic efficacy.
Why Did the Assays, Kits, & Reagents Segment Hold a 45% Share for the Companion Diagnostics Market?
The assays, kits, & reagents segment held a dominant position in the market with a share of 45% in 2025. Owing to its high demand for standardized testing solutions. It is predominantly used in cancer treatment to match patients with precise therapies. Assays are needed to detect specific biomarkers or low-frequency gene mutations.
The instruments and systems segment held a 35% share of the market in 2025, with the boom in precision oncology and immunotherapies requiring complex biomarker profiling. It mandates advanced, high-throughput systems to accurately stratify patients. Continuous upgrades in automation, AI-based analysis, and multiplexing capabilities force diagnostics centers to invest in modernized equipment to remain compliant and competitive.
The software and services segment held a 20% share of the market in 2025, due to the growing demand for remote pathology and integrated software platforms that allow healthcare providers to streamline lab processes, ensure accuracy, and make faster clinical decisions across different locations. The specialized software solutions are required to accurately analyze this data, interpret complex biomarkers, and guide targeted therapies.
Why Did the Oncology Segment Hold a 50% Share for the Companion Diagnostics Market?
The oncology segment held a dominant position in the market with a share of 50% in 2025. Owing to the companion diagnostics are primarily used in targeted cancer therapies. The increasing prevalence of various cancers necessitates earlier, more accurate detection and customized treatment strategies.
The infectious diseases segment held a 20% share of the market in 2025, with the widespread testing capability seamlessly expanded into the co-development of targeted antiviral therapeutics. The alarming increases in drug-resistant pathogens have made it essential to identify the exact genetic markers of resistance before prescribing broad-spectrum antibiotics.
The cardiovascular diseases segment held a 10% share of the market in 2025, due to the increasing integration of pharmacogenomic and genotyping, which allows clinicians to identify actionable biomarkers, optimizing drug dosing for critical cardiovascular conditions, such as thrombosis and heart failure. By analyzing specific patient genes such as CYP2C19 and CYP2C9, these biomarkers, driven tests minimize severe adverse drug reactions and significantly improve overall therapeutic outcomes.
The neurological disorders segment held a 8% share of the market in 2025, due to the rapid aging of the global population surge in neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and multiple sclerosis. Innovation in next-generation sequencing and digital biomarker detection has made significant easier to identify molecular and genetic characteristics in the brain. The increasing co-development of diagnostic tests alongside novel neurological drugs to secure parallel regulatory approvals.
The others indicators segment held a 12% share of the market in 2025, with targeted therapies increasingly penetrating non-oncology fields, such as immunology, virology, and cardiovascular diseases, broadening the clinical footprint of personalized medicine. The global regulatory bodies encouraging drug-diagnostic co-development, these emerging indicators ensure patients receive highly precise therapies tailored to their unique molecular profiles.
Why Did the Polymerase Chain Reaction (PCR) Segment Lead the Companion Diagnostics Market?
The polymerase chain reaction (PCR) segment registered its dominance over the market with a share of 30% in 2025, owing to the widespread use in diagnosis. Rapid analytical capability yields critical diagnostic results in hours, allowing medical professionals to swiftly stratify patients and accelerate access to targeted therapies. PCR remains a highly cost-effective, globally standardized methodology that requires lower capital investment and infrastructure compared to complex sequencing platforms.
The next-generation sequencing (NGS) segment held the 25% share of the market in 2025, with the ability to simultaneously evaluate multiple complex biomarkers and gene alterations to accurately predict patient response to immunotherapies. This comprehensive multiplexing capability preserves scarce tissue samples by replacing dozens of single-target assays with a single, highly efficient diagnostic run.
The in-situ hybridization (ISH) segment held the 15% share of the market in 2025, due to preserving crucial spatial and morphological context, allowing clinicians to visually map biomarkers directly within intact tumor structures rather than relying on tissue harmonization. Despite the deeply entrenched regulatory pathways and decades of clinical validation, ISH remains a low-risk, trusted diagnostic methodology for global pharmaceutical co-development.
The immunohistochemistry (IHC) segment held the 15% share of the market in 2025, providing direct visualization of target proteins, demonstrating exactly how biomarkers localize within intact tumor architecture rather than relying on genomic homogenization. With the extensive portfolio of FD-approved companion assays and deeply entrenched pathology workflow, ICH remains a globally trusted, low-risk standard for personalized medicine.
The magnetic resonance imaging (MRI) segment held the 10% share of the market in 2025, owing to the advanced techniques like fMRI and magnetic resonance spectroscopy, which provide the vital functional and molecular data required to assess targeted therapies. Crucially, this repeatable, non-invasive approach directly addresses the rising global burden of chronic cancers and neurological disorders without exposing patients to cumulative radiation risks.
The other technology segment held the 5% share of the market in 2025. With the supportive regulatory climate, these diverse methodologies are successfully expanding companion testing beyond cancer care into rapidly growing therapeutic sectors like neurology, cardiovascular medicine, and rare orphan diseases.
Why Did the Tissue Samples Segment Lead the Companion Diagnostics Market?
The tissue samples segment registered its dominance over the market with a share of 55% in 2025, owing to the vast majority of commercial companion diagnostics being strictly engineered for physical tissue validation. Solid biopsies continue to command undisputed market dominance in personalized cancer care. The major technological breakthroughs in next-generation sequencing, immunohistochemistry, and AI-enabled digital pathology have transformed tissue analysis into a rapid, highly precise, and standardized workflow.
The blood samples segment held the 35% share of the market in 2025, enabling continuous, real-time monitoring of circulating tumor DNA and other viral biomarkers. Blood samples allow clinicians to track tumor progression, evaluate treatment efficacy, and detect relapses as they happen. The massive technological breakthroughs in the sensitivity of Next-Generation Sequencing and PCR are rapidly transforming the blood segment into a highly agile and accessible medical discipline.
The other sample types segment held the 10% share of the market in 2025, due to the essential need for assessing hematological malignancies, such as leukemia, ensuring accurate patient stratification for specialized, targeted therapies. The continuous global rollout of targeted drugs for complex chronic conditions accelerates the demand for these highly diverse, condition-specific sample matrices to accurately identify niche biomarkers.
Why Did the Hospitals & Physician Laboratories Segment Lead the Companion Diagnostics Market?
The hospitals & physician laboratories segment registered its dominance over the market with a share of 35% in 2025, owing to the integrated care systems, which facilitate streamlined testing workflows, enabling doctors to seamlessly coordinate diagnostic insights with targeted drug prescriptions for complex diseases. Its unique ability to support comprehensive genomic profiling to guide high-cost immunotherapies cements hospitals and clinics as a driving companion.
The academic & research centers segment held the 15% share of the market in 2025, due to the robust government grants and private funding dedicated to oncology drug development, these facilitate possesses the financial resources to aggressively scale early-stage research. Its excellence in translational medicine bridges the gap between basic laboratory science and commercial diagnostic applications, forging vital partnerships with major pharmaceutical and biotechnology companies.
The CROs segment held the 10% share of the market in 2025, due to providing smaller pharmaceutical and biotech firms with an established global regulatory pathway, advanced clinical trial management, and deep biomarker validation experience. Its localized regulatory knowledge across diverse international markets streamlines global approval timelines, cementing CROs as an indispensable engine driving companion diagnostic commercialization.
The reference laboratories segment held the 15% share of the market in 2025, with the aggregation of large-scale test volumes, which facilitates achieving significant economies of scale, allowing them to deliver highly cost-effective and rapid turnaround times for specialized diagnostic evaluations. With the increasing global burden of oncology and rare genetic disorders, healthcare providers increasingly outsource specialized companion diagnostic testing to these certified facilities rather than establishing expensive in-house testing pipelines.
The pharmaceutical & biotechnology companies segment held the 20% share of the market in 2025, with the enhanced drug efficacy and patient safety identification of precise patient subgroups that will respond positively to specialized treatments while minimizing adverse effects. This predictive capability directly supports the global boom in targeted oncology and immunology therapeutics, ensuring high-cost medications are strictly prescribed to patients with matching biomarker profiles.
Why Did the North America Region Lead the Companion Diagnostics Market?
The North America region registered its dominance over the market with a share of 40% in 2025, owing to the well-established, structured reimbursement policies across the region, which ensure superior patient access to high-cost genomic testing and targeted therapies compared to other regions. With the rapid clinical adoption of next-generation sequencing and AI-integrated diagnostics, the region achieves rapid turnaround times that continuously optimize targeted therapy selection and cement its leadership.
U.S. Surgical Suture Market Trends
The U.S. has a strong clinical preference in deep tissue surgeries, where they safely eliminate the need for secondary removal. To combat surgical site infections and actively promote faster tissue healing, leading medical manufacturers are increasingly integrating specialized antimicrobial and antibacterial coatings into their product lines. The adoption of advanced barbed and knotless sutures is surging across high-precision fields, such as plastic surgery, because they significantly reduce procedure times and ensure highly consistent wound tension.
The Europe region held the 20% share of the market in 2025, due to the rising demand for precision oncology, as major healthcare markets, such as Germany, France, and the UK shift away from standard treatments to combat growing chronic disease burdens. The joint development costs are significantly mitigated by strategic research funding from the European Commission and localized genomic medicine programs that rapidly accelerate diagnostic commercialization.
U.K. Surgical Suture Market Trends
The U. K’s rapid adoption of specialized antibacterial coatings and advanced barbed designs, which maximize wound closure efficiency while significantly reducing post-operative surgical site infections. This regions hospital are increasing integrating automated suturing devices to support complex, minimally invasive operations, allowing surgeons to execute deep-tissue closures with unmatched procedural precision.
The Asia Pacific segment held 20% share of the market in 2025, due to the increasing incidence of cancer across the region, which has accelerated the need for accurate, early-stage detection and personalized treatments. Expanding investment in next-generation sequencing platforms and AI-enabled diagnostics solutions has made targeted testing more accessible across the region.
China Surgical Suture Market Trends
China’s rising prevalence of minimally invasive procedures requires advanced suturing technologies, growing the demand for specialized, high-precision products. Accelerating shift toward antibacterial and monofilament suture as these materials reduce the risk of surgical site infections compared to braided alternatives.
The Latin America region held 6% share of the market in 2025, with the increasing incidence of chronic diseases, particularly various types of cancer, necessitating accurate biomarker testing to ensure optimal patient outcomes. The expanding private healthcare networks and diagnostic laboratories that offer advanced molecular testing independent of public reimbursement models.
The MEA region held 4% share of the market in 2025, due to the region's shift toward early detection and biomarker-driven therapies. The rapid growth of medical wellness and specialized healthcare tourism pushed hospitals to adopt cutting-edge, precision-based companion diagnostics platforms to cater to international clinical standards.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has companion diagnostics market.
By Product and Service
By Indication
By Technology
By Sample Type
By End Use
By Regional
Companion Diagnostics Market
Download Sample
Request Customization
Request Customization
Download Sample